HE4与CA125联合应用ROMA用于上皮性卵巢癌的风险评估

目的 探究HE4与CA125联合应用ROMA指数用于上皮性卵巢癌的风险评估的价值.方法 临床回顾并随访从2013年1月至2016年10月期间在高淳人民医院治疗的患者194例,经石蜡切片病理报告诊断卵巢癌患者84例,卵巢良性疾病110例,同时选取无任何疾病史的健康女性50例.研究并比较各组中人附睾蛋白4以及血清糖类抗原125的指标水平,通过公式计算各组ROMA指数(PP),并根据结果结合绝经状态预测及评价卵巢恶性肿瘤的发病风险.HE4、CA125水平检测采用全自动化学发光微粒子免疫分析方法.结果 卵巢癌组各项指标表达水平均高于健康组(P<0.05),差异具有统计学意义.良性卵巢疾病组CA125及ROMA高于健康组,但两组HE4差异无统计学意义(P>0.05).HE4的灵敏度略高于CA125,但特异性却明显优于CA125.同时,HE4阳性表达率与年龄有一定的相关性,ROMA阳性表达率与年龄和绝经状态均呈相关性.结论 HE4的灵敏度及特异性都较理想,HE4和CA125联合应用ROMA指数用于上皮性卵巢癌风险评估具有重要的临床意义.

HE4 and CA125 Combined with ROMA Index for Epithelial Ovarian Risk

Objective To explore the value of HE4 and CA125 combined with ROMA index for assessing the risk of epithelial ovarian cancer.Methods 194 cases of patients in People′s Hospital of Gaochun County from January 2012 to October 2014 were reviewed and followed up.84 cases of ovarian cancer and 110 cases of benign ovarian disease were diagnosed by paraffin section pathological report.Meanwhile, 50 healthy women with no disease history were selected randomly.The indicators of HE4 and CA125 in each group were analyzed.The ROMA index (PP) of each group was calculated by the formula, and combined with the risk prediction and evaluation of ovarian malignant tumor according to the results of the state of despair.HE4, CA125 level were detected with full automatic chemiluminescence micro particle immunoassay method.Results The expression level of each index in ovarian cancer group was significantly higher than that in healthy group (P<0.05).CA125 and ROMA in the benign ovarian disease group were higher than those in the healthy group, but there was no significant difference between the two groups (P>0.05).The sensitivity of HE4 was slightly higher than that of CA125, but the specificity is obviously better than CA125.At the same time, the positive expression rate of HE4 was correlated with age,the positive expression rate of ROMA was correlated with age and menopausal status.Conclusion The sensitivity and specificity of HE4 could be a ideal method.The combination of HE4 and ROMA might have important clinical significance for the risk assessment of epithelial ovarian cancer.